PersonGen BioTherapeutics to Participate at ACCESS CHINA Biotech Forum

By Yafo Life Sciences

December 31st, 2021 (Shanghai) — We are glad to announce that Nan Yang, the BD Director of PersonGen BioTherapeutics, has been invited to showcase at ACCESS CHINA Biotech Forum during Jan 4th – Jan13th. ACCESS CHINA Biotech Forum is the largest online corporate access event between China and the western biopharma industry.

If you are interested in listening to the live event, please register at https://biotochina.org/register/

About PersonGen BioTherapeutics

PersonGen is a Chinese BioTech company aiming to develop high efficacy but low-cost cellular therapeutics that cancer patients really need. Founded in 2010, PersonGen has turned into a state-level high-tech enterprise focusing on developing first-in-class and best-in-class CAR-T cell drugs. Its R&D center is equipped with state-of-art of cell therapy and molecular biology infrastructure. Its Cell Manufacturing center is armed with a pipeline in accordance with national NMPA standard including a GMP workshop for CAR-T cell production, a GMP workshop for plasmid and lentivirus production and purification, a P2 safety laboratory, and a quality control laboratory. In addition of equipped with the outstanding facilities, PersonGen’s team of R&D and cellular industrialization is technically competent with strong expertise in cell therapeutics. Until now, PersonGen has independently developed several first-in-class and best-in-class therapeutic cellular products, covering most hematological tumors and some solid tumors. Among them, first-in-class PA3-17 injection for T-lymphoblastic leukemia/lymphoma is the first autologous CD7-CAR-T cell drug candidate in the world that was approved for registered clinical trials, and it was designated as an orphan drug by the US FDA; the TAA06 cell injection, developed for treating solid tumors in children and adults, has demonstrated outstanding tumor clearance efficacy in preclinical studies, and is now entering into the IND application phase in China as well as is planning clinical trials overseas.

About Nan Yang

Nan Yang (PhD in molecular biology), ~30 years R&D experiences in genetics and other medical related areas; ~20 years molecular diagnosis related experiences; ~10 years biomedical marketing and business development experiences. Medal of Friendship award from Hefei government (2020). Excellent award in supervising postgraduate students from Children’s Hospital at Westmead, Sydney University (2010). One of 100 world the most important scinece and technology discoveries (2004). Several other awards.


ACCESS CHINA is the most effective deal-making platform for Western pharma and biotech leaders looking to enter or expand in the Chinese market. ACCESS CHINA creates invaluable BD opportunities by directly connecting and meeting with the right partners for development, licensing or commercial collaborations. View more information at https://biotochina.org/access-china-forum/

Contact US

Register ACCESS CHINA online, please visit: ACCESS CHINA Biotech Forum

For more information, please contact:

Wendi Xiang